- $1.03tn
- $1.07tn
- $65.18bn
UK Stocks-Factors to watch on June 12
UK approves Novo weight-loss pill to edge open European market (updated)
Novo Nordisk rises after UK health regulator approves its weight-loss pill
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Race to launch weight-loss pill heats up as Novo wins UK approval
UK health regulator approves Novo Nordisk's weight-loss pill
Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases
Pfizer CEO warns German investment at risk over drug pricing policies (updated)
Novo Nordisk faces off in court with South African weight-loss drug compounder
Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon
U.S. RESEARCH ROUNDUP- Datadog, Eli Lilly, Oracle
Global Markets: Equities lose some steam while dollar falls and oil slips
Global Markets: Stocks rally as investors dive back into tech; oil slips
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Roche sticks to German investment after Eli Lilly cuts
AlzeCure signs collaboration, out-licensing deal with Lilly for Alzheimer's drug
Brief: Alzecure Pharma Enters Into Collaboration, Out-Licensing Agreement With Lilly For Alzheimer’s Project
Use of GLP-1 drugs early in pregnancy should not cause alarm, analysis suggests (updated)
Use of GLP-1 drugs early in pregnancy should not cause alarm